2017 News Releases

Jun-05-2017

Bioblast Pharma to Seek Strategic Alternatives Including Partnership and Merger Opportunities

JSB-Partners Engaged to Lead the Effort Company Receives Regulatory Clearance to Initiate a Phase 2b trial of Trehalose in OPMD patients TEL AVIV, Israel, June 05, 2017 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (NasdaqCM:ORPN), a clinical-stage, orphan disease-focused biotechnology company, today announced that it has engaged JSB-Partners, a global life sciences advisor, to assist the Company in executing its business development objectives that include selecting potential development and co... 

Continue reading

May-26-2017

Bioblast Pharma Reports First Quarter 2017 Financial Results

TEL AVIV, Israel, May 26, 2017 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage, orphan disease-focused biotechnology company, today announced financial results for the first quarter ended March 31, 2017. First Quarter 2017 Financial Results and Cash Position R&D Expenses: Research and development expenses were $1.1 million for the quarter ended March 31, 2017, compared to $1.9 million for the same period in 2016. The decrease was primarily related to reduce... 

Continue reading

Apr-17-2017

Bioblast Pharma Announces Plans in Response to Nasdaq Notifications Regarding Stockholders’ Equity and Minimum Bid Requirements

TEL AVIV, Israel, April 17, 2017 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage, orphan disease-focused biotechnology company, announced today that in response to a written notification from the Listing Qualifications Department of The NASDAQ Stock Market LLC that the Company does not satisfy the Nasdaq Global Market continued listing requirement set forth in Nasdaq Stock Market Rule 5450(b)(1)(A) which requires that the company maintain a minimum of $10,000,000 in st... 

Continue reading

Apr-06-2017

Bioblast Announces Termination of Securities Offering

TEL AVIV, Israel, April 06, 2017 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage, orphan disease-focused biotechnology company, announced today the cancellation of its previously announced underwritten public offering of the company’s securities due to adverse market conditions.  The offering was conducted pursuant to a registration statement Form F-1 filed with the U.S. Securities and Exchange Commission. The Company will provide a business update in the near futur... 

Continue reading

Apr-06-2017

Bioblast Pharma Announces Termination of Securities Offering

TEL AVIV, Israel, April 06, 2017 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage, orphan disease-focused biotechnology company, announced today the cancellation of its previously announced underwritten public offering of the Company’s securities due to adverse market conditions.  H.C. Wainwright had been serving as the underwriters for the proposed offering.  The offering was conducted pursuant to a registration statement Form F-1 filed with the U.S. Securities and Exc... 

Continue reading

Mar-10-2017

Bioblast Pharma Announces Receipt of Nasdaq Notification Regarding Stockholders’ Equity

TEL AVIV, Israel, March 10, 2017 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage, orphan disease-focused biotechnology company, announced today that it received a written notification from the Listing Qualifications Department of The NASDAQ Stock Market LLC. The notification advised that the company’s stockholders’ equity, as reported in the company’s Annual Report on Form 20-F for the fiscal year ended December 31, 2016, does not satisfy the Nasdaq Global Market conti... 

Continue reading

Feb-24-2017

Bioblast Pharma Reports Fourth Quarter and Year End 2016 Financial Results

TEL AVIV, Israel, Feb. 24, 2017 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage, orphan disease-focused biotechnology company, today announced financial results for the fourth quarter ended December 31, 2016 and other recent developments. Key Corporate Developments: Completed clinical trials: As previously announced on January 18, 2017, the Company reported the results of a six-month open label Phase 2a clinical trial that also included an additional six-month f... 

Continue reading

Feb-01-2017

Bioblast Pharma Provides Clinical and Development Updates on Trehalose as a Potential Therapeutic for OPMD and Other Neurodegenerative Diseases

Investor Lunch and Live Webcast at 12 noon Eastern Time Tomorrow TEL AVIV, Israel, Feb. 01, 2017 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (NasdaqGM:ORPN), a clinical-stage, orphan disease-focused biotechnology company, announced new clinical and development updates related to its proprietary intravenous (IV) form of trehalose 90 mg/mL solution, which is being evaluated as a potential therapeutic, initially for oculopharyngeal muscular dystrophy (OPMD). Bioblast management will provide a co... 

Continue reading

Jan-26-2017

Bioblast Pharma to Host Key Opinion Leader Lunch Focused on Orphan Neurological Diseases on February 2

Investor Lunch and Live Webcast at 12 Noon Eastern Time on February 2 TEL AVIV, Israel, Jan. 26, 2017 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage, orphan disease-focused biotechnology company, will host a KOL lunch on the subject of orphan neurological diseases and treatments at 12pm on Thursday, February 2, 2017 in New York City. Bioblast management will provide an overview of the Company’s ongoing clinical development work with trehalose 90 mg/mL IV solution,... 

Continue reading

Jan-18-2017

Bioblast Announces Phase 2a Results of Trehalose in Patients with Spinocerebellar Ataxia Type 3 (SCA3)

Patients Treated with Trehalose Remained Stable According to a Well-Established Clinical Evaluation Scale A Recent Natural History Study in The Lancet Neurology in Patients with SCA3 Noted a Steady Disease Progression Over Time              TEL AVIV, Israel, Jan. 18, 2017 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage, orphan disease-focused biotechnology company, today announced results of a six-month open label Phase 2a study that also included an additional six-m... 

Continue reading